Insmed (NASDAQ:INSM) Price Target Raised to $258.00

Insmed (NASDAQ:INSM) had its target price increased by The Goldman Sachs Group from $225.00 to $258.00 in a report released on Monday morning,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biopharmaceutical company’s stock.

INSM has been the topic of a number of other reports. Royal Bank Of Canada boosted their target price on Insmed from $139.00 to $215.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Redburn Partners set a $263.00 price target on Insmed in a research note on Thursday, December 4th. Bank of America boosted their price objective on shares of Insmed from $142.00 to $187.00 and gave the stock a “buy” rating in a research report on Monday, October 27th. Rothschild Redb upgraded shares of Insmed to a “strong-buy” rating in a report on Thursday, December 4th. Finally, Guggenheim upped their price target on shares of Insmed from $125.00 to $172.00 and gave the company a “buy” rating in a report on Monday, September 8th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $200.89.

Insmed Trading Down 1.1%

Shares of INSM opened at $198.46 on Monday. Insmed has a twelve month low of $60.40 and a twelve month high of $212.75. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $42.33 billion, a P/E ratio of -32.06 and a beta of 1.01. The firm’s 50-day moving average is $187.37 and its two-hundred day moving average is $142.14.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The company had revenue of $142.34 million for the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. Insmed’s revenue was up 52.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.27) earnings per share. On average, research analysts predict that Insmed will post -4.56 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Elizabeth M. Anderson sold 5,000 shares of Insmed stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $204.58, for a total transaction of $1,022,900.00. Following the completion of the sale, the director directly owned 58,729 shares in the company, valued at $12,014,778.82. The trade was a 7.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $194.00, for a total transaction of $5,820,000.00. Following the transaction, the insider directly owned 36,461 shares in the company, valued at $7,073,434. The trade was a 45.14% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 147,130 shares of company stock valued at $28,480,051 over the last quarter. 3.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Insmed

Hedge funds have recently made changes to their positions in the business. Darwin Global Management Ltd. increased its stake in Insmed by 5.8% in the third quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company’s stock valued at $2,897,797,000 after purchasing an additional 1,112,824 shares during the last quarter. Vanguard Group Inc. grew its holdings in Insmed by 13.0% in the 3rd quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock valued at $2,870,957,000 after buying an additional 2,291,328 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Insmed by 1.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company’s stock valued at $985,938,000 after acquiring an additional 219,131 shares during the last quarter. Capital International Investors lifted its holdings in shares of Insmed by 1.0% during the 3rd quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock worth $1,087,830,000 after acquiring an additional 74,994 shares during the period. Finally, Artisan Partners Limited Partnership boosted its position in shares of Insmed by 49.0% in the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after acquiring an additional 1,623,342 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.